p53/cGAS/STING pathway

Overview

The p53/cGAS/STING pathway links genome surveillance to innate immune activation. Two systems converge in it: the tumor suppressor TP53, which arrests the cell cycle or triggers apoptosis and cellular senescence when the genome is damaged, and the cGAS–STING sensor (cyclic GMP-AMP synthase and Stimulator of interferon Genes, encoded by STING1), which detects DNA where DNA should not be. Cytosolic DNA is a signature of infection or of catastrophe in the nucleus, and the cell treats both alike. Chromosome mis-segregation and unrepaired damage leave lagging fragments enclosed in micronuclei whose envelopes are fragile and rupture, spilling genomic DNA into the cytosol; cGAS binds it in a length-dependent manner, synthesizes the second messenger cGAMP, and cGAMP activates STING at the endoplasmic reticulum, which recruits TBK1 to phosphorylate IRF3 and, with NF-κB, drives type I interferon and inflammatory cytokine transcription. p53 sits upstream of the supply of such ligands, since arresting a damaged cell before it divides limits the mitotic errors that generate micronuclei in the first place.

The consequences depend on whether the signal is acute or sustained. A burst of interferon after radiation or chemotherapy recruits and licenses dendritic cells, which is part of how DNA-damaging therapy provokes an immune response and reprograms the tumor microenvironment. Chronic low-grade activation instead sustains the inflammatory secretions of senescent cells and, in tumors that have learned to tolerate it, can be turned to immune evasion — which is why loss of cGAS or STING expression is common in Cancers with high chromosomal instability.

Therapeutically the axis has proved harder than expected. Synthetic STING agonists produce strong interferon responses in models but have disappointed in trials, limited by delivery, by the fact that STING signaling can also induce T-cell death, and by the same tumor-intrinsic silencing. Beyond oncology, aberrant activity drives neuroinflammation in vascular and neurodegenerative disease, and STING1 signaling in alveolar macrophages contributes to pulmonary fibrotic remodeling, making inhibition rather than activation the goal in those settings.

Recent Publications Summary

Recent studies have examined the p53/cGAS/STING pathway primarily as a signaling axis that can be therapeutically modulated to reshape inflammation, cellular senescence, and antitumor immunity. In breast cancer, a carrier-free nanomedicine co-assembled from the STING agonist SR717 and the photosensitizer Ce6 was designed to synchronize photodynamic therapy with STING activation, producing strong CD8+ T-cell infiltration and suppressing both primary and distant tumors in a murine model 42370321Jun. In pancreatic cancer, a smart-responsive lentinan-DMXAA conjugate was developed to deliver the STING agonist DMXAA with enzyme- and pH-responsive release, promoting STING-dependent dendritic cell maturation, antigen presentation, and tumor growth inhibition 42173385May. A related nanomedicine approach in hepatocellular carcinoma combined piezocatalytic reactive oxygen species generation with parallel PANoptosis and STING activation to convert cold tumors into hot ones and drive immune-cell deployment 42308311Jun.

Beyond cancer, several publications linked this pathway to inflammatory and degenerative disease mechanisms. In diabetic retinopathy, elevated aqueous humor dsDNA and retinal pigment epithelial dysfunction were associated with cGAS-STING pathway activation, and pharmacological STING inhibition reduced cytoplasmic dsDNA accumulation, mitochondrial damage, inflammation, and vascular changes 42149122May. In age-related bone loss, trimethylamine N-oxide (TMAO) was shown to induce osteoblast cellular senescence and osteogenic dysfunction through cGAS-STING-NF-κB signaling, while STING knockdown mitigated these effects in vivo 42366244Jun. In pulmonary fibrosis, inhalable lipid nanoparticle enabled macrophage-specific Sting1 gene editing, suppressing downstream STING signaling and reducing pro-fibrotic cytokine secretion 41795185Mar.

Other studies focused on direct STING targeting in inflammatory disorders. In silicosis, glycyrrhetinic acid-3-O-β-D-glucuronide (GAMG) was identified as a direct STING binder that inhibited the STING/TBK1/NF-κB pathway and reduced inflammatory and fibrotic mediators in macrophages and in a murine model 42341724Jun. In psoriasis, Yinxie Granules were reported to alleviate cutaneous inflammation and vasculopathy by specifically targeting the STING/NF-κB pathway, with differential activation of STING/IRF3 and STING/NF-κB signaling observed across disease severity. In clear cell renal cell carcinoma, the APC/C adaptor Cdh1 was found to stabilize STING by preventing SPOP-mediated degradation, thereby potentiating type I interferon signaling and innate immune activation 42335217Jun.

A separate study in vascular cognitive impairment reported that Buyang Huanwu Decoction alleviated neuroinflammation through regulation of the p53/cGAS/STING pathway 41638453Feb. Together, these publications portray the p53/cGAS/STING pathway as a convergent node for controlling innate immune activation, inflammatory injury, cellular cellular senescence, and tumor immunotherapy, with interventions ranging from small molecules and traditional medicines to engineered nanoplatforms and gene-editing delivery systems 42370321Jun42366244Jun42341724Jun42335217Jun41638453Feb.

What Changes, What Holds

1. Therapeutic modulation now looks like the main way this axis is being operationalized in cancer
REINFORCES These studies do not revise the baseline mechanism; they extend its translational use by showing that STING activation can be deliberately paired with photodynamic injury, enzyme/pH-responsive delivery, or ROS-generating nanoplatforms to amplify antitumor immunity. The p53/cGAS/STING pathway remains a convergent stress-immune axis, but the new work strengthens the case that its most immediate clinical value may be in combination immunotherapy rather than as a standalone target 42370321Jun42173385May.

2. The pathway is now implicated in disease-driving senescence and tissue injury outside the baseline’s main examples
NEW DIRECTION These findings broaden the overview’s disease map by tying cGAS-STING activity to diabetic retinopathy and age-related bone loss, where STING inhibition or knockdown reduced inflammatory, mitochondrial, and senescence-associated damage. That adds a new role for the axis in metabolic and skeletal degeneration, while the pulmonary fibrosis result fits the established fibrotic theme and mainly sharpens cell-type specificity through macrophage-directed gene editing 42149122May42366244Jun41795185Mar.

3. Direct STING suppression and stabilization emerge as opposing therapeutic levers, but both still support the same inflammatory model
REINFORCES GAMG and Yinxie Granules point to STING/TBK1/NF-κB as a druggable inflammatory node, while Cdh1-mediated STING stabilization in renal cancer reinforces the idea that preserving STING can enhance type I interferon signaling in antitumor immunity. The mixed direction is not a contradiction of the baseline; it shows that benefit depends on context, with inhibition favored in inflammatory disease and stabilization favored where immune activation is desirable 42341724Jun42335217Jun.

4. Traditional medicine is now being used to tune the p53/cGAS/STING axis in neuroinflammation
NEW DIRECTION Buyang Huanwu Decoction extends the overview into vascular cognitive impairment, a setting the baseline did not specifically cover, and suggests that p53/cGAS/STING regulation may be relevant to neurovascular inflammation beyond the broader neurodegenerative and vascular pathologies already mentioned. The evidence is early and preclinical, so it mainly opens a new therapeutic direction rather than settling mechanism or clinical utility 41638453Feb.

Overview update candidates: disease expansion to diabetic retinopathy and age-related bone loss; macrophage-specific Sting1 editing in pulmonary fibrosis; p53/cGAS/STING regulation in vascular cognitive impairment.